CRISPR Therapeutics (CRSP) Misses Q4 EPS by 20c
Tweet
Share
E-mail
Get Alerts CRSP Hot Sheet
Join SI Premium – FREE
CRISPR Therapeutics (NASDAQ: CRSP) reported Q4 EPS of ($1.37), $0.20 worse than the analyst estimate of ($1.17). Revenue for the quarter came in at $860 thousand versus the consensus estimate of $5.66 million.
For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FOMC minutes from July 28-29th meeting
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- Trump on Clarity Act: we need Congress to pass it
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
